Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
541 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05082675 | Stem Cell Translpantation in Multiple Myeloma | completed | Phase 2 | 357 | European Society for Blood and Marrow TransplantationNETWORK | 11 | Sep 11, 2023 | clinicaltrials |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | completed | Phase 2 | 206 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 21, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | completed | Phase 2 | 90 | GenmabINDUSTRY | 11 | Aug 3, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT03003520 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 46 | CelgeneINDUSTRY | 5 | May 22, 2023 | clinicaltrials |
| NCT04752059 | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases(TUXEDO-1) | completed | Phase 2 | 15 | Medical University of ViennaOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC(YH001) | withdrawn | Phase 2 | 0 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | terminated | Phase 2 / Phase 3 | 1 | Nektar TherapeuticsINDUSTRY | 4 | Jan 12, 2023 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT02996110 | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma(FRACTION-RCC) | completed | Phase 2 | 182 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 19, 2022 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02917772 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma(TITAN-RCC) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 8 | Oct 6, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03144687 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | completed | Phase 2 | 23 | Incyte CorporationINDUSTRY | 3 | Jun 16, 2022 | clinicaltrials |
| NCT01887522 | Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults(VINILO) | terminated | Phase 2 | 144 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 8 | May 31, 2022 | clinicaltrials |
| NCT03101475 | Synergism of Immunomodulation and Tumor Ablation(ILOC) | completed | Phase 2 | 22 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 31, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT02138955 | A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer | completed | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide | completed | Phase 2 | 563 | Puma Biotechnology, Inc.INDUSTRY | 7 | May 6, 2022 | clinicaltrials |
| NCT00710710 | Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT02212015 | Evaluation of Votrient in Angiosarcoma(EVA) | terminated | Phase 2 | 26 | Heidelberg UniversityOTHER | 2 | Mar 22, 2022 | clinicaltrials |
| NCT03617133 | Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer(EMBRACEII) | recruiting | Phase 2 | 1,000 | Medical University of ViennaOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT00951457 | Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 20 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02462538 | Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL | terminated | Phase 1 / Phase 2 | 3 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02987400 | Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL | completed | Phase 2 | 22 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02639910 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi(COSMOS) | completed | Phase 2 | 24 | MorphoSys AGINDUSTRY | 6 | Dec 20, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT03219775 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma(TITAN-TCC) | unknown | Phase 2 | 169 | AIO-Studien-gGmbHOTHER | 2 | Nov 3, 2021 | clinicaltrials |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 13, 2021 | clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT02743429 | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma | unknown | Phase 2 | 40 | University Medicine GreifswaldOTHER | 2 | Oct 4, 2021 | clinicaltrials |
| NCT02406742 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(ENHANCE) | completed | Phase 1 / Phase 2 | 47 | CelgeneINDUSTRY | 5 | Sep 20, 2021 | clinicaltrials |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control(NIVOSWITCH) | terminated | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | unknown | Phase 2 / Phase 3 | 60 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials